Journal Home > Volume 1 , Issue 1
iLIVER 2022, 1(1): 3-11 https://doi.org/10.1016/j.iliver.2022.04.002
Review | Open Access | Issue | Published: 18 April 2022

Liver transplantation for malignant liver tumors

Show Author's Information Richard X. Sousa Da Silvaa,b,  Beat Muellhauptc,  Philipp Dutkowskia,b,  Pierre-Alain Claviena,b ( )
Department of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) and Transplant Center, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
Wyss Zurich, ETH Zurich, University of Zurich, Weinbergstrasse 35, 8006 Zurich, Switzerland
Department of Gastroenterology and Hepatology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
Keywords:
Liver transplantation, Selection criteria, Malignant tumor, Machine perfusion, Tumor recurrence
Cite this article:
Sousa Da Silva RX, Muellhaupt B, Dutkowski P, et al. Liver transplantation for malignant liver tumors. iLIVER, 2022, 1(1): 3-11. https://doi.org/10.1016/j.iliver.2022.04.002
Download citation
EndNote(RIS)
BibTeX

758

Views

41

Downloads

Citations

5

Crossref

N/A

WoS

N/A

Scopus

N/A

CSCD

Abstract Full text About this article

Liver transplantation is a highly effective treatment not only for acute or chronic liver failure but also for primary liver cancer such as hepatocellular carcinoma, perihilar cholangiocarcinoma, intrahepatic cholangiocarcinoma, and metastatic tumors such as from neuroendocrine or colorectal liver metastases. The success strongly relies on strict adherence to stringent selection criteria, which lead to excellent outcomes, while previously regarded as contraindication for liver transplantation. These impressive results are, however, mostly achieved with a combination of pretreatment strategies and convincing control of the tumor growth prior to transplantation, as well as minimizing long-term immunosuppression. With this emergence of oncologic liver transplantation, we expect an increasing need of grafts, and therefore included in this report strategies to improve the number of available grafts by maximizing liver utilization rates. Modern machine liver perfusion approaches may play in this respect an important role.


menu
Abstract
Full text
Outline
About this article

Liver transplantation for malignant liver tumors

Show Author's information Richard X. Sousa Da Silvaa,b, Beat Muellhauptc, Philipp Dutkowskia,b, Pierre-Alain Claviena,b ( )
Department of Surgery and Transplantation, Swiss Hepato-Pancreato-Biliary (HPB) and Transplant Center, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
Wyss Zurich, ETH Zurich, University of Zurich, Weinbergstrasse 35, 8006 Zurich, Switzerland
Department of Gastroenterology and Hepatology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland

Abstract

Liver transplantation is a highly effective treatment not only for acute or chronic liver failure but also for primary liver cancer such as hepatocellular carcinoma, perihilar cholangiocarcinoma, intrahepatic cholangiocarcinoma, and metastatic tumors such as from neuroendocrine or colorectal liver metastases. The success strongly relies on strict adherence to stringent selection criteria, which lead to excellent outcomes, while previously regarded as contraindication for liver transplantation. These impressive results are, however, mostly achieved with a combination of pretreatment strategies and convincing control of the tumor growth prior to transplantation, as well as minimizing long-term immunosuppression. With this emergence of oncologic liver transplantation, we expect an increasing need of grafts, and therefore included in this report strategies to improve the number of available grafts by maximizing liver utilization rates. Modern machine liver perfusion approaches may play in this respect an important role.

Keywords: Liver transplantation, Selection criteria, Malignant tumor, Machine perfusion, Tumor recurrence

References(116)

[1]

Zarrinpar A, Busuttil RW. Timeline Liver transplantation: past, present and future. Nat Rev Gastroenterol Hepatol 2013;10(7): 434-40.
DOI Google Scholar
[2]

Starzl TE, Iwatsuki S, Vanthiel DH, et al. Evolution of liver-transplantation. Hepatology 1982;2(5): 614-36.
Google Scholar
[3]

Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012;57(3): 675-88.
DOI Google Scholar
[4]

Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New Engl J Med 1996; 334(11): 693-9.
DOI Google Scholar
[5]

Clavien PA, Lesurtel M, Bossuyt PMM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13(1): E11-22.
DOI Google Scholar
[6]

Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imag 2013;12: 530-47.
DOI Google Scholar
[7]

Tasdogan BE, Ma M, Simsek C, Saberi B, Gurakar A. Update on immunosuppression in liver transplantation. Euroasian J Hepato-Gastroenterol 2019;9(2): 96-101.
DOI Google Scholar
[8]

Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski P, Clavien PA. Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Rev Gastroenterol Hepatol 2020;17(12): 755-72.
DOI Google Scholar
[9]

Ivanics T, Abreu P, De Martin E, Sapisochin G. Changing trends in liver transplantation: challenges and solutions. Transplantation 2021;105(4): 743-56.
DOI Google Scholar
[10]

Menon VG, Chen Y, Chang DC, Yeh H. Waiting list mortality of liver tumors. Am J Transplant 2020;20: 1061. 1061.
DOI Google Scholar
[11]

Lai JC, Ganger DR, Volk ML, et al. Association of frailty and sex with wait list mortality in liver transplant candidates in the multicenter functional assessment in liver transplantation (FrAILT) study. Jama Surgery 2021;156(3): 256-62.
DOI Google Scholar
[12]

Rahimi RS. Association between liver transplant wait-list mortality and frailty based on body mass index (vol 489, pg 783, 2019). Jama Surgery 2019;154(12): 1171.
Google Scholar
[13]

Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Prim 2021;7(1).
DOI Google Scholar
[14]

Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol 2017; 14(4): 203-17.
DOI Google Scholar
[15]

Trinchet JC, Bourcier V, Chaffaut C, et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 2015;62(3): 737-50.
DOI Google Scholar
[16]

Tarao K, Nozaki A, Ikeda T, et al. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med-Us 2019;8(3): 1054-65.
DOI Google Scholar
[17]

Yang JD, Larson JJ, Watt KD, et al. Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the United States. Clin Gastroenterol Hepatol 2017;15(5): 767[+].
DOI Google Scholar
[18]

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16(10): 589-604.
DOI Google Scholar
[19]

Haldar D, Kern B, Hodson J, et al. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a European Liver Transplant Registry study. J Hepatol 2019;71(2): 313-22.
DOI Google Scholar
[20]

Mehta N. Liver transplantation criteria for hepatocellular carcinoma, including posttransplant management. Clin Liver Dis 2021;17(5): 332-6.
DOI Google Scholar
[21]

Sherman M. Recurrence of hepatocellular carcinoma. New Engl J Med 2008; 359(19): 2045-7.
DOI Google Scholar
[22]

Saito A, Toyoda H, Kobayashi M, et al. Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learning. Mod Pathol 2021;34(2): 417-25.
DOI Google Scholar
[23]

Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res 2019;49(10): 1109-13.
DOI Google Scholar
[24]

Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129(1): 113-21.
DOI Google Scholar
[25]

Jansen PLM. Non alcoholic steatohepatitis - Introduction. Eur J Gastroenterol Hepatol 2004;16(11): 1079-85.
DOI Google Scholar
[26]

Nagaoki Y, Hyogo H, Aikata H, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res 2012;42(4): 368-75.
DOI Google Scholar
[27]

Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013;10(11): 656-65.
DOI Google Scholar
[28]
Med NASE. Eliminating the public health problem of hepatitis B and C in the United States: phase one report. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. 2016. p. 1-171.
[29]

Alshuwaykh O, Kwo PY. Current and future strategies for the treatment of chronic hepatitis C. Clin Mol Hepatol 2021;27(2): 246-56.
DOI Google Scholar
[30]

Wang WT, Guo YX, Zhong JT, et al. The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. Sci Rep-Uk 2021;11(1).
DOI Google Scholar
[31]

Lee YH, Hsu CY, Huang YH, et al. Vascular invasion in hepatocellular carcinoma prevalence, determinants and prognostic impact. J Clin Gastroenterol 2014;48(8): 734-41.
DOI Google Scholar
[32]

Ho WJ, Zhu QF, Durham J, et al. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nat Can (Que) 2021;2(9): 891[+].
DOI Google Scholar
[33]

Sotiropoulos GC, Lang H, Frilling A, et al. Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature. Hepato-Gastroenterology 2006; 53(69): 322-9.
Google Scholar
[34]

She WH, Chok K. Strategies to increase the resectability of hepatocellular carcinoma. World J Hepatol 2015;7(18): 2147-54.
DOI Google Scholar
[35]

Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33(6): 1394-403.
DOI Google Scholar
[36]

Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-Expanded criteria based on preoperative imaging. Am J Transplant 2007;7(11): 2587-96.
DOI Google Scholar
[37]

Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 2018;154(1): 128-39.
DOI Google Scholar
[38]

Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007;7(6): 1601-8.
DOI Google Scholar
[39]

Li FY, Li JG, Wu SS, et al. An optimal ablative margin of small single hepatocellular carcinoma treated with image-guided percutaneous thermal ablation and local recurrence prediction base on the ablative margin: a multicenter study. J Hepatocell Carcinoma 2021;8: 1375-88.
DOI Google Scholar
[40]

Zhu FP, Rhim H. Thermal ablation for hepatocellular carcinoma: what's new in 2019. Chin Clin Oncol 2019;8(6).
DOI Google Scholar
[41]

Okusaka T, Kasugai H, Shioyama Y, et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase Ⅲ trial. J Hepatol 2009;51(6): 1030-6.
DOI Google Scholar
[42]

Noren A, Urdzik J, Duraj F, Barbier CE, Karlson BM, Haglund U. Longterm followup after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre. HPB 2010;12(9): 637-43.
DOI Google Scholar
[43]

Ang MK, Poon D, Foo KF, et al. A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematol Oncol Stem Cell Ther 2008;1(3): 159-65.
DOI Google Scholar
[44]

Holowko W, Wroblewski T, Wojtaszek M, et al. Transarterial chemoembolization prior to liver transplantation in patients with hepatocellular carcinoma. Ann Transplant 2015;20.
DOI Google Scholar
[45]

Otto G, Heise M, Hoppe-Lotichius M, Hansen T, Woerns M, Pttion M. TACE as bridging to liver transplantation in patients with hepatocellular carcinoma: are milan criteria suitable for patient selection? Transplantation 2012;94(10): 638.
DOI Google Scholar
[46]

Wang EA, Broadwell SR, Bellavia RJ, Stein JP. Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma. J Gastrointest Oncol 2017;8(2): 266-78.
DOI Google Scholar
[47]

Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl 2015;21(9): 1142-52.
DOI Google Scholar
[48]

Fernandez-Sevilla E, Allard MA, Selten J, et al. Recurrence of hepatocellular carcinoma after liver transplantation: is there a place for resection? Liver Transpl 2017;23(4): 440-7.
DOI Google Scholar
[49]

Shirabe K, Taketomi A, MoritaK, et al. Comparative evaluation of expanded criteriafor patients with hepatocellular carcinoma beyond the Milan criteria undergoing livingrelated donor liver transplantation. Clin Transplant 2011;25(5): E491-8.
DOI Google Scholar
[50]

Serrablo A, Tejedor L. Outcome of surgical resection in Klatskin tumors. World J Gastrointest Oncol 2013;5(7): 147-58.
DOI Google Scholar
[51]

Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg 2013;258(1): 129-40.
DOI Google Scholar
[52]

Klempnauer J, Ridder GJ, Werner M, Weimann A, Pichlmayr R. What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer 1997;79(1): 26-34.
DOI
[53]

Iwatsuki S, Todo S, Marsh JW, et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998; 187(4): 358-64.
DOI Google Scholar
[54]

Sudan D, DeRoover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002;2(8): 774-9.
DOI Google Scholar
[55]

Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242(3): 451-61.
DOI Google Scholar
[56]

Hassoun Z, Gores GJ, Rosen CB. Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma. Surg Oncol Clin 2002;11(4): 909-21.
DOI Google Scholar
[57]

Ethun CG, Lopez-Aguiar AG, Anderson DJ, et al. Transplantation versus resection for hilar cholangiocarcinoma an argument for shifting treatment paradigms for resectable disease. Ann Surg 2018;267(5): 797-805.
DOI Google Scholar
[58]

Murad SD, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012;143(1): 88-U610.
DOI Google Scholar
[59]

Resch T, Esser H, Cardini B, Schaefer B, Zoller H, Schneeberger S. Liver transplantation for hilar cholangiocarcinoma (h-CCA): is it the right time? Transl Gastroent Hep 2018;3.
DOI Google Scholar
[60]

Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer 2020;126(11): 2666-78.
DOI Google Scholar
[61]

Buettner S, van Vugt JLA, Ijzermans JNM, Koerkamp BG. Intrahepatic cholangiocarcinoma: current perspectives. OncoTargets Ther 2017;10: 1131-42.
DOI Google Scholar
[62]

Pawlik TM, Pulitano C, Alexandrescu S, et al. Intrahepatic cholangiocarcinoma: an international, multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011;29(4).
DOI Google Scholar
[63]

Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology 2016;64(4): 1178-88.
DOI Google Scholar
[64]

Lee DD, Croome KP, Musto KR, et al. Liver transplantation for intrahepatic cholangiocarcinoma. Liver Transpl 2018;24(5): 634-44.
DOI Google Scholar
[65]

Sapisochin G, Javle M, Lerut J, et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ILTS transplant oncology consensus conference. Transplantation 2020;104(6): 1125-30.
DOI Google Scholar
[66]

Sapisochin G, Rodriguez de Lope C, Gastaca M, et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? Am J Transplant 2014;14(3): 660-7.
DOI Google Scholar
[67]

Sapisochin G, Fernandez de Sevilla E, Echeverri J, Charco R. Liver transplantation for cholangiocarcinoma: current status and new insights. World J Hepatol 2015; 7(22): 2396-403.
DOI Google Scholar
[68]

Lunsford KE, Javle M, Heyne K, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol 2018;3(5): 337-48.
DOI Google Scholar
[69]

Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol 2020;12(10): 693-708.
DOI Google Scholar
[70]

Pietge H, Sanchez-Velazquez P, Akhoundova D, et al. Combination of HAI-FUDR and systemic gemcitabine and cisplatin in unresectable cholangiocarcinoma: a dose finding single center study. Oncology 2021;99(5): 300-9.
DOI Google Scholar
[71]

Tian G, Zhao Q, Chen F, Jiang T, Wang W. Ablation of hepatic malignant tumors with irreversible electroporation: a systematic review and meta-analysis of outcomes. Oncotarget 2017;8(4): 5853-60.
DOI Google Scholar
[72]

Sweeney J, Parikh N, El-Haddad G, Kis B. Ablation of intrahepatic cholangiocarcinoma. Semin Intervent Radiol 2019;36(4): 298-302.
DOI Google Scholar
[73]

Finotti M, Vitale A, Gringeri E, et al. Colon rectal liver metastases: the role of the liver transplantation in the era of the transplant oncology and precision medicine. Front Surg 2021;8.
DOI Google Scholar
[74]

Lim C, Farges O. Portal vein occlusion before major hepatectomy in patients with colorectal liver metastases: rationale, indications, technical aspects, complications and outcome. J Vis Surg 2012;149(2): E86-96.
DOI Google Scholar
[75]

Laurent C, Fernandez B, Marichez A, et al. Radiological simultaneous portohepatic vein embolization (RASPE) before major hepatectomy A better way to optimize liver hypertrophy compared to portal vein embolization. Ann Surg 2020;272(2): 199-205.
DOI Google Scholar
[76]

Clavien PA. Hepatic vein embolization for safer liver surgery insignificant novelty or a breakthrough? Ann Surg 2020;272(2): 206-9.
DOI Google Scholar
[77]

de Santibanes E, Clavien PA. Playing Play-Doh to prevent postoperative liver failure: the "ALPPS" approach. Ann Surg 2012;255(3): 415-7.
DOI Google Scholar
[78]

Buisman FE, Filipe WF, Kemeny NE, et al. Recurrence after liver resection of colorectal liver metastases: repeat resection or ablation followed by hepatic arterial infusion pump chemotherapy. Ann Surg Oncol 2021;28(2): 808-16.
DOI Google Scholar
[79]

Giuliante F, Ardito F, Ferrero A, et al. Tumor progression during preoperative chemotherapy predicts failure to complete 2-stage hepatectomy for colorectal liver metastases: results of an Italian multicenter analysis of 130 patients. J Am Coll Surg 2014;219(2): 285-94.
DOI Google Scholar
[80]

Smedman TM, Line PD, Hagness M, Syversveen T, Grut H, Dueland S. Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-Ⅱ arm D study). Bjs Open 2020;4(3): 467-77.
DOI Google Scholar
[81]

Hagness M, Foss A, Line PD, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 2013;257(5): 800-6.
DOI Google Scholar
[82]

Dueland S, Syversveen T, Solheim JM, et al. Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases. Ann Surg 2020;271(2): 212-8.
DOI Google Scholar
[83]

Xiang ZW, Sun L, Li GH, Maharjan R, Huang JH, Li CX. Progress in the treatment of pulmonary metastases after liver transplantation for hepatocellular carcinoma. World J Hepatol 2015;7(20): 2309-14.
DOI Google Scholar
[84]

Line PD, Hagness M, Berstad AE, Foss A, Dueland S. A novel concept for partial liver transplantation in nonresectable colorectal liver metastases: the RAPID concept. Ann Surg 2015;262(1). e5-9.
DOI Google Scholar
[85]

Konigsrainer A, Templin S, Capobianco I, et al. Paradigm shift in the management of irresectable colorectal liver metastases: living donor auxiliary partial orthotopic liver transplantation in combination with two-stage hepatectomy (LD-RAPID). Ann Surg 2019;270(2): 327-32.
DOI Google Scholar
[86]

Ravaioli M, Fallani G, Cescon M, et al. Heterotopic auxiliary segment 2-3 liver transplantation with delayed total hepatectomy: new strategies for nonresectable colorectal liver metastases. Surgery 2018;164(3): 601-3.
DOI Google Scholar
[87]

Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 2017;18(4): 525-34.
DOI Google Scholar
[88]

Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plockinger U. Multimodal management of neuroendocrine liver metastases. HPB 2010;12(6): 361-79.
DOI Google Scholar
[89]

Cloyd JM, Ejaz A, Konda B, Makary MS, Pawlik TM. Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobil Surg Nutr 2020;9(4): 440-51.
DOI Google Scholar
[90]

Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014;15(1): E8-21.
DOI Google Scholar
[91]

Ngo L, Elnahla A, Attia AS, et al. Chemoembolization versus radioembolization for neuroendocrine liver metastases: a meta-analysis comparing clinical outcomes. Ann Surg Oncol 2021;28(4): 1950-8.
DOI Google Scholar
[92]

Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review. Surgery 2017;162(3): 525-36.
DOI Google Scholar
[93]

Mazzaferro V, Sposito C, Coppa J, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant 2016;16(10): 2892-902.
DOI Google Scholar
[94]

Hindie E. The NETPET score: combining FDG and somatostatin receptor imaging for optimal management of patients with metastatic well-differentiated neuroendocrine tumors. Theranostics 2017;7(5): 1159-63.
DOI Google Scholar
[95]

Yu JJ, Xiao W, Dong SL, et al. Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma. BMC Cancer 2018;18(1): 835.
DOI Google Scholar
[96]

Line PD, Dueland S. Liver transplantation for secondary liver tumours: the difficult balance between survival and recurrence. J Hepatol 2020;73(6): 1557-62.
DOI Google Scholar
[97]

Vigano S, Perreau M, Pantaleo G, Harari A. Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. Clin Dev Immunol 2012;2012: 485781.
DOI Google Scholar
[98]

Wang S, Yang FJ, Wang X, et al. PARP-1 promotes tumor recurrence after warm ischemic liver graft transplantation via neutrophil recruitment and polarization. Oncotarget 2017;8(51): 88918-33.
DOI Google Scholar
[99]

Grat M, Krawczyk M, Wronka KM, et al. Ischemia-reperfusion injury and the risk of hepatocellular carcinoma recurrence after deceased donor liver transplantation. Sci Rep 2018;8(1): 8935.
DOI Google Scholar
[100]

Mueller M, Kalisvaart M, O'Rourke J, et al. Hypothermic oxygenated liver perfusion (HOPE) prevents tumor recurrence in liver transplantation from donation after circulatory death. Ann Surg 2020;272(5): 759-65.
DOI Google Scholar
[101]

Dutkowski P, Guarrera JV, de Jonge J, Martins PN, Porte RJ, Clavien PA. Evolving trends in machine perfusion for liver transplantation. Gastroenterology 2019; 156(6): 1542-7.
DOI Google Scholar
[102]

Harun N, Nikfarjam M, Muralidharan V, Christophi C. Liver regeneration stimulates tumor metastases. J Surg Res 2007;138(2): 284-90.
DOI Google Scholar
[103]

Shi JH, Line PD. Effect of liver regeneration on malignant hepatic tumors. World J Gastroenterol 2014;20(43): 16167-77.
DOI Google Scholar
[104]

Shi JH, Huitfeldt HS, Suo ZH, Line PD. Growth of hepatocellular carcinoma in the regenerating liver. Liver Transpl 2011;17(7): 866-74.
DOI Google Scholar
[105]

Shetty S, Lalor PF, Adams DH. Liver sinusoidal endothelial cells - gatekeepers of hepatic immunity. Nat Rev Gastroenterol Hepatol 2018;15(9): 555-67.
DOI Google Scholar
[106]

Park MS, Lee KW, Suh SW, et al. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation. Transplantation 2014;97(1): 71-7.
DOI Google Scholar
[107]

Tian T, Li X, Zhang J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci 2019;20(3).
DOI Google Scholar
[108]

Eiden AM, Zhang SL, Gary JM, Simmons JK, Mock BA. Molecular pathways: increased susceptibility to infection is a complication of mTOR inhibitor use in cancer therapy. Clin Cancer Res 2016;22(2): 277-83.
DOI Google Scholar
[109]

Rodriguez-Peralvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013;59(6): 1193-9.
DOI Google Scholar
[110]
Doyle MB, Vachharajani N, Maynard E, et al. Liver transplantation for hepatocellular carcinoma: long-term results suggest excellent outcomes. J Am Coll Surg 2012;215(1): 19-28. discussion 28-30.https://doi.org/10.1016/j.jamcollsurg.2012.02.022
DOI
[111]

Acher AW, Weber SM, Pawlik TM. Liver transplantation for perihilar cholangiocarcinoma: patient selection and outcomes. Expert Rev Gastroenterol Hepatol 2021;15(5): 555-66.
DOI Google Scholar
[112]

Mantel HTJ, Westerkamp AC, Adam R, et al. Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival. PLoS One 2016;11(6).
DOI Google Scholar
[113]

Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma - an analysis of 103 patients. Transplantation 1998;66(10): 1307-12.
DOI Google Scholar
[114]

Rosenau J, Bahr MJ, von Wasielewski R, et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 2002;73(3): 386-94.
DOI Google Scholar
[115]

LeTreut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors - a 31-case French multicentric report. Ann Surg 1997;225(4): 355-64.
DOI Google Scholar
[116]

Liao X, Zhang D. The 8th edition American Joint committee on cancer staging for hepato-pancreato-biliary cancer: a review and update. Arch Pathol Lab Med 2021; 145(5): 543-53.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Received: 01 March 2022
Revised: 08 April 2022
Accepted: 08 April 2022
Published: 18 April 2022
Issue date: March 2022

Copyright

© 2022 The Authors. Published by Elsevier Ltd on behalf of Tsinghua University Press.

Rights and permissions

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Return